Ragifilimab
- Generic Name
- Ragifilimab
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
- Conditions
- Cancer of the Head and Neck
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 56
- Registration Number
- NCT04470024
- Locations
- 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 39
- Registration Number
- NCT04225039
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
- Conditions
- Advanced MalignanciesMetastatic Cancer
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Incyte Biosciences International SÃ rl
- Target Recruit Count
- 10
- Registration Number
- NCT03277352
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
- Conditions
- Advanced MalignanciesMetastatic Cancer
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Incyte Biosciences International SÃ rl
- Target Recruit Count
- 145
- Registration Number
- NCT03126110
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Washington University - Siteman Cancer Center, Saint Louis, Missouri, United States
Biomarker-based Study in R/M SCCHN
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2023-11-03
- Target Recruit Count
- 340
- Registration Number
- NCT03088059
- Locations
- 🇧🇪
CHU Saint-Pierre-Site Porte de Hal, Brussels, Belgium
🇮🇹IRCCS - Fondazione G. Pascale, Napoli, Italy
🇬🇧Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Incyte Biosciences International SÃ rl
- Target Recruit Count
- 100
- Registration Number
- NCT02697591
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MSK Westchester, Harrison, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.